Hyperparathyroidism is diagnosed primarily through blood tests that measure two things at the same time: calcium and parathyroid hormone (PTH). When both are elevated together, that combination is the definitive finding. Most people discover they have it after a routine blood panel catches high calcium, which prompts further testing to find the cause.
The Two Key Blood Tests
The cornerstone of diagnosis is a simple pairing: serum calcium and PTH measured from the same blood draw. Normal total calcium in adults runs between 8.8 and 10.4 mg/dL, while ionized (free) calcium normally falls between 4.6 and 5.3 mg/dL. In primary hyperparathyroidism, calcium is elevated and PTH is simultaneously high or inappropriately normal. That word “inappropriately” matters. Your body should respond to high calcium by shutting PTH production down to nearly undetectable levels. When PTH stays elevated despite high calcium, it means the parathyroid glands are ignoring the signal to stop.
Most other causes of high calcium, such as certain cancers or excessive vitamin D, produce appropriately suppressed PTH. So the combination of high calcium plus high PTH effectively narrows the diagnosis to hyperparathyroidism or one uncommon genetic mimic called familial hypocalciuric hypercalcemia (more on that below). Phosphorus levels add another clue. Low phosphorus alongside high calcium is highly suggestive, though not enough on its own to confirm the diagnosis.
Urine Testing to Rule Out a Genetic Mimic
Once blood tests point toward hyperparathyroidism, most doctors order a 24-hour urine collection. You collect all your urine over a full day so the lab can measure how much calcium your kidneys are excreting. The main purpose is to distinguish primary hyperparathyroidism from familial hypocalciuric hypercalcemia (FHH), a rare inherited condition that looks almost identical on blood tests, with high calcium and normal or slightly elevated PTH.
The key difference is what your kidneys do with calcium. In hyperparathyroidism, the kidneys excrete a lot of calcium into the urine. In FHH, the kidneys hold onto calcium tightly. Doctors calculate a calcium-to-creatinine clearance ratio from the urine sample. A ratio below 0.01 suggests FHH, while a ratio above 0.02 points toward primary hyperparathyroidism. Values between those numbers fall into a gray zone where genetic testing for mutations in the calcium-sensing receptor gene may be needed to settle the question. Getting this distinction right is critical because FHH is benign and requires no treatment, while unnecessary surgery would not help.
How Secondary Hyperparathyroidism Is Different
Not all hyperparathyroidism starts in the parathyroid glands themselves. In secondary hyperparathyroidism, the glands are overworking because something else is driving calcium levels down, most commonly chronic kidney disease or severe vitamin D deficiency. The blood test pattern looks different from the primary form. Instead of high calcium, you typically see normal or low calcium, low vitamin D, and in later kidney disease, high phosphorus. PTH rises as a compensating response rather than as the root problem.
The biochemical diagnosis still relies on measuring PTH, but doctors interpret the result in context. A patient with advanced kidney disease and rising PTH is following a predictable pattern: the kidneys can no longer activate vitamin D properly, calcium absorption drops, and the parathyroid glands ramp up to compensate. Treating the underlying cause, whether it’s replacing vitamin D or managing kidney function, is the priority rather than targeting the parathyroid glands directly.
Bone Density Scanning
Once hyperparathyroidism is confirmed through blood and urine tests, a bone density scan (DXA) is part of the standard workup. What makes this condition unique is that it preferentially damages cortical bone, the dense outer layer found in high concentrations at the forearm. Hyperparathyroidism is actually the only condition for which guidelines specifically recommend scanning the forearm in addition to the usual hip and spine measurements.
A T-score of -2.5 or lower at any site, including the lumbar spine, hip, femoral neck, or distal forearm, is one of the criteria that may tip the decision toward surgery in someone who otherwise has no symptoms. One study found that adding forearm measurement increased the number of patients who met surgical criteria, meaning the forearm scan catches bone loss that would otherwise go undetected.
Imaging to Locate the Problem Gland
Imaging scans are not used to diagnose hyperparathyroidism. They are used after diagnosis to locate which of the four parathyroid glands is overactive, typically an adenoma (a benign tumor), so a surgeon can plan a targeted operation. The three main options are neck ultrasound, a nuclear medicine scan called sestamibi, and a newer technique called 4D CT.
Ultrasound is usually the first step because it involves no radiation and a positive result is reliable. However, its sensitivity is limited, detecting adenomas in roughly 32% of cases in one large study. Sestamibi scans perform similarly, at about 26% sensitivity, though they are highly specific, meaning when they do identify a gland, it is very likely the correct one.
4D CT has emerged as a significant improvement. It detected adenomas in about 76% of patients, and it was especially useful for finding glands in unusual locations that ultrasound and sestamibi missed entirely. In one study, 4D CT identified 48 adenomas that both ultrasound and sestamibi had failed to detect, with nearly half of those sitting in ectopic (abnormal) positions. For patients with negative or inconclusive results on initial imaging, 4D CT is increasingly considered essential.
When Diagnosis Happens Without Symptoms
Many people are diagnosed with hyperparathyroidism before they ever feel anything wrong. High calcium shows up on a routine blood panel, further testing confirms the diagnosis, and the question becomes whether to proceed with surgery or monitor over time. Specific criteria guide that decision. Surgery is generally recommended for asymptomatic patients who meet any of the following:
- Calcium level more than 1.0 mg/dL above the upper limit of normal
- Bone density T-score of -2.5 or lower at any measured site
- Vertebral fracture found on imaging
- Kidney involvement, including kidney stones, calcium deposits in the kidneys, or urine calcium above 400 mg per day with elevated stone risk
- Reduced kidney function with creatinine clearance below 60 mL/min
- Age younger than 50
Patients who don’t meet any of these criteria can often be safely monitored with regular blood tests and periodic bone density scans, though many still choose surgery for a definitive cure.
Supplements That Can Distort Test Results
If you take biotin supplements, they can interfere with PTH and calcium blood tests. Biotin is common in hair, skin, and nail supplements, sometimes at doses of 5 mg or more. In sandwich-type lab assays, which are the standard method for measuring PTH, high biotin levels in your blood can produce falsely low PTH readings. This could mask hyperparathyroidism or create confusing results that delay diagnosis. One documented case showed that stopping biotin and repeating the labs a month later returned PTH and calcium values to their true levels. If you take biotin, mention it to your doctor before testing. Stopping the supplement for at least several days before a blood draw is typically enough to avoid interference.